Breast Cancer News and Research

Latest Breast Cancer News and Research

Breath test to detect cancer: Study

According to researchers cancer may soon be detectable using a breath test. They are now developing sensors that can detect chemical markers of lung, breast, bowel and prostate cancer in a person's breath. The new portable device has been purported as an “electronic nose” that can detect early cancers. As a cancer grows, the surface of the cells emits chemicals. The research found that sensors – involving gold nanoparticles – could be used to detect these chemicals in the breath.

10 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Research on role of ADAM12 gene in breast cancer

A microscopic gene may play a gigantic role when it comes to cancerous tissue in the human body, according to one Kansas State University research team.The team is investigating mutation within the ADAM12 gene of the A Disintegrin and Metalloprotease family, or ADAM family, and its role in breast cancer."We want to know whether ADAM12 is a good guy or a bad guy in breast cancer," said Anna Zolkiewska, associate professor of biochemistry and research team leader.

10 Aug 2010

Scientist to research on molecular machinery of breast cancer

Someone in the world is diagnosed with breast cancer every 23 seconds. It is the leading cause of cancer death worldwide among women and approximately 456,000 die from the disease each year. At The University of Texas Health Science Center at Houston (UTHealth), a scientist is taking aim at the molecular machinery behind this disease.

10 Aug 2010

Study to evaluate sensitivity of mammography combined with somo•v ABUS technology in breast cancer screening

Henry Ford West Bloomfield Hospital announced today that it has joined U-Systems national clinical research study designed to evaluate whether digital mammography, when combined with the somo•v Automated Breast Ultrasound System (ABUS) from U-Systems, Inc (Sunnyvale, CA), is more sensitive in detecting breast lesions compared to mammography alone in women with dense breasts. Henry Ford West Bloomfield Hospital is the only site in Michigan, and one of only ten breast cancer centers in the entire country, currently recruiting women for the SOMO•INSIGHT clinical study.

10 Aug 2010

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

9 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

GTx second-quarter net loss increases to $12.9 million

GTx, Inc. today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009. The net loss for the second quarter of 2010 included a $1.7 million non-cash impairment charge related to the conclusion of the Phase III clinical trial of toremifene 20 mg.

9 Aug 2010

ESMO Congress provides forum for presentation of new research on treatment of cancer

Cancer is a leading cause of mortality worldwide, accounting for more than one in ten deaths. By 2030, the global burden is expected to exceed 12 million.

9 Aug 2010

Oil Can Henry's customers raise $45,401 to support Susan G. Komen for the Cure

Oil Can Henry's customers rose to the challenge in July and helped the company raise $45,401 to support the Oregon and SW Washington Affiliate of Susan G. Komen for the Cure to help save lives and end breast cancer. Over the week-long fundraising effort, Oil Can Henry's locations in Oregon and Southwest Washington performed oil changes on 15,746 vehicles. In addition, customers had the opportunity to donate directly to Komen at the time of service.

7 Aug 2010

BCF publishes two new patient publications

The Bone and Cancer Foundation is announcing the publishing of two new patient publications on Pain Management and Physical Therapy and other Rehabilitation Therapies. Other publication topics include: Breast Cancer, Prostate Cancer, Lung Cancer, Osteonecrosis of the Jaw, Vitamin D, Surgery, Myeloma and Osteosarcoma.

7 Aug 2010

Norwegian cervical screening program begins reimbursing for liquid-based cytology

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that on July 1, 2010, the Norwegian cervical screening program began reimbursing for liquid-based cytology (LBC).

6 Aug 2010

Researchers identify gene associated with susceptibility to chronic pain caused by nerve injury

Researchers at the Hebrew University of Jerusalem and elsewhere have succeeded in identifying for the first time a gene associated with susceptibility to chronic pain caused by nerve injury in humans, signaling a significant step toward better understanding and treating of the condition.

6 Aug 2010

Agendia inaugurates new clinical genomics laboratory

Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.

6 Aug 2010

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages.

5 Aug 2010

Incyte second-quarter total revenues increase to $49.8 million

Incyte Corporation today reported second quarter 2010 financial results and described progress for several of its clinical programs.

5 Aug 2010

Scientists discover gene linked to eight-fold risk of breast cancer recurrence

Cancer Research UK scientists have discovered that a gene called POLQ is linked to an eight-fold risk of breast cancer returning. Developing drugs to block POLQ could increase survival and stop the cancer coming back, according to research published in OncoTarget.

5 Aug 2010

Gene associated with susceptibility to chronic pain caused by nerve injury identified

Researchers at the Hebrew University of Jerusalem and elsewhere have succeeded in identifying for the first time a gene associated with susceptibility to chronic pain caused by nerve injury in humans, signalling a significant step toward better understanding and treating of the condition.

5 Aug 2010

CTI second-quarter total net operating expenses decrease to $20.0 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the second quarter ended June 30, 2010.

5 Aug 2010

Breast Cancer News and Research

Latest Breast Cancer News and Research

Breath test to detect cancer: Study

Synta second-quarter net loss increases to $9.1 million

Research on role of ADAM12 gene in breast cancer

Scientist to research on molecular machinery of breast cancer

Study to evaluate sensitivity of mammography combined with somo•v ABUS technology in breast cancer screening

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

GTx second-quarter net loss increases to $12.9 million

ESMO Congress provides forum for presentation of new research on treatment of cancer

Oil Can Henry's customers raise $45,401 to support Susan G. Komen for the Cure

BCF publishes two new patient publications

Norwegian cervical screening program begins reimbursing for liquid-based cytology

Researchers identify gene associated with susceptibility to chronic pain caused by nerve injury

Agendia inaugurates new clinical genomics laboratory

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Incyte second-quarter total revenues increase to $49.8 million

Scientists discover gene linked to eight-fold risk of breast cancer recurrence

Gene associated with susceptibility to chronic pain caused by nerve injury identified

CTI second-quarter total net operating expenses decrease to $20.0 million

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Breast Cancer News and Research

Latest Breast Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in